Overview

Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The aim of this pilot-study is to investigate the effect of Vildagliptin in comparison to glimepiride on beta cell function and the cardiovascular risk profile in patients previously treated with Metformin monotherapy.

Phase:

Phase 4

Details

Lead Sponsor:

ikfe-CRO GmbH

Collaborators:

IKFE Institute for Clinical Research and Development
Novartis Pharmaceuticals

Treatments:

Glimepiride
Metformin
Vildagliptin